Caveolin-1: an ambiguous entity in breast cancer
Abstract Breast cancer (BC) is the most frequently diagnosed cancer in women and the second leading cause of death from cancer among women. Metastasis is the major cause of BC-associated mortality. Accumulating evidence implicates Caveolin-1 (Cav-1), a structural protein of plasma membrane caveolae,...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-025-02297-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850145699574841344 |
|---|---|
| author | Naveen Chintalaramulu Dhirendra Pratap Singh Biplov Sapkota Dayanidhi Raman Suresh Alahari Joseph Francis |
| author_facet | Naveen Chintalaramulu Dhirendra Pratap Singh Biplov Sapkota Dayanidhi Raman Suresh Alahari Joseph Francis |
| author_sort | Naveen Chintalaramulu |
| collection | DOAJ |
| description | Abstract Breast cancer (BC) is the most frequently diagnosed cancer in women and the second leading cause of death from cancer among women. Metastasis is the major cause of BC-associated mortality. Accumulating evidence implicates Caveolin-1 (Cav-1), a structural protein of plasma membrane caveolae, in BC metastasis. Cav-1 exhibits a dual role, as both a tumor suppressor and promoter depending on the cellular context and BC subtype. This review highlights the role of Cav-1 in modulating glycolytic metabolism, tumor-stromal interactions, apoptosis, and senescence. Additionally, stromal Cav-1's expression is identified as a potential prognostic marker, offering insights into its contrasting roles in tumor suppression and progression. Furthermore, Cav-1's context-dependent effects are explored in BC subtypes including hormone receptor-positive, HER2-positive, and triple-negative BC (TNBC). The review further delves into the role of Cav-1 in regulating the metastatic cascade including extracellular matrix interactions, cell migration and invasion, and premetastatic niche formation. The later sections discuss the therapeutic targeting of Cav-1 by metabolic inhibitors such as betulinic acid and Cav-1 modulating compounds. While Cav-1 may be a potential biomarker and therapeutic target, its heterogeneous expression and context-specific activity necessitates further research to develop precise interventions. Future studies investigating the mechanistic role of Cav-1 in metastasis may pave the way for effective treatment of metastatic BC. |
| format | Article |
| id | doaj-art-efc6506065b84ae3b92cf0e4035df4bf |
| institution | OA Journals |
| issn | 1476-4598 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj-art-efc6506065b84ae3b92cf0e4035df4bf2025-08-20T02:28:02ZengBMCMolecular Cancer1476-45982025-04-0124112110.1186/s12943-025-02297-8Caveolin-1: an ambiguous entity in breast cancerNaveen Chintalaramulu0Dhirendra Pratap Singh1Biplov Sapkota2Dayanidhi Raman3Suresh Alahari4Joseph Francis5Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State UniversityKrannert Cardiovascular Research Center, Indiana University HealthDepartment of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State UniversityDepartment of Cell and Cancer Biology, University of Toledo Health Science CampusSchool of Medicine, LSU HealthDepartment of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State UniversityAbstract Breast cancer (BC) is the most frequently diagnosed cancer in women and the second leading cause of death from cancer among women. Metastasis is the major cause of BC-associated mortality. Accumulating evidence implicates Caveolin-1 (Cav-1), a structural protein of plasma membrane caveolae, in BC metastasis. Cav-1 exhibits a dual role, as both a tumor suppressor and promoter depending on the cellular context and BC subtype. This review highlights the role of Cav-1 in modulating glycolytic metabolism, tumor-stromal interactions, apoptosis, and senescence. Additionally, stromal Cav-1's expression is identified as a potential prognostic marker, offering insights into its contrasting roles in tumor suppression and progression. Furthermore, Cav-1's context-dependent effects are explored in BC subtypes including hormone receptor-positive, HER2-positive, and triple-negative BC (TNBC). The review further delves into the role of Cav-1 in regulating the metastatic cascade including extracellular matrix interactions, cell migration and invasion, and premetastatic niche formation. The later sections discuss the therapeutic targeting of Cav-1 by metabolic inhibitors such as betulinic acid and Cav-1 modulating compounds. While Cav-1 may be a potential biomarker and therapeutic target, its heterogeneous expression and context-specific activity necessitates further research to develop precise interventions. Future studies investigating the mechanistic role of Cav-1 in metastasis may pave the way for effective treatment of metastatic BC.https://doi.org/10.1186/s12943-025-02297-8Breast CancerMetastasisCaveolin-1PrognosisAnti-Cav-1 therapy |
| spellingShingle | Naveen Chintalaramulu Dhirendra Pratap Singh Biplov Sapkota Dayanidhi Raman Suresh Alahari Joseph Francis Caveolin-1: an ambiguous entity in breast cancer Molecular Cancer Breast Cancer Metastasis Caveolin-1 Prognosis Anti-Cav-1 therapy |
| title | Caveolin-1: an ambiguous entity in breast cancer |
| title_full | Caveolin-1: an ambiguous entity in breast cancer |
| title_fullStr | Caveolin-1: an ambiguous entity in breast cancer |
| title_full_unstemmed | Caveolin-1: an ambiguous entity in breast cancer |
| title_short | Caveolin-1: an ambiguous entity in breast cancer |
| title_sort | caveolin 1 an ambiguous entity in breast cancer |
| topic | Breast Cancer Metastasis Caveolin-1 Prognosis Anti-Cav-1 therapy |
| url | https://doi.org/10.1186/s12943-025-02297-8 |
| work_keys_str_mv | AT naveenchintalaramulu caveolin1anambiguousentityinbreastcancer AT dhirendrapratapsingh caveolin1anambiguousentityinbreastcancer AT biplovsapkota caveolin1anambiguousentityinbreastcancer AT dayanidhiraman caveolin1anambiguousentityinbreastcancer AT sureshalahari caveolin1anambiguousentityinbreastcancer AT josephfrancis caveolin1anambiguousentityinbreastcancer |